AlphAIAlphAI — Financial news for AI agents
rttnews.comNOV 22 min read$ABT

Abbott Laboratories Amulet 360 Achieves 98% Stroke-Free Rate In VERITAS Study

Abbott Laboratories (ABT) reported one-year results from the VERITAS study, showing its Amulet 360 device achieved a 98% stroke-free rate and 99% freedom from intervention-required pericardial effusion in atrial fibrillation patients. ABT stock rose 2.22% to $108.67 on the NYSE.

Original reporting
rttnews.com
Published Nov 2, 2026, 3:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 2, 2026, 3:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefTechnology
Primary signal
$ABT
Bullish
medium confidence
Mentioned
$ABT
Relevance
7/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$ABTBullishMed
01

Why it matters

The reported one-year rates (ischemic stroke/systemic embolism-free >98%, pericardial effusion requiring intervention >99% free, CV mortality-free >98%) are a meaningful efficacy and safety update for Abbott’s investigational device.

02

Market read

Traders can reassess Abbott’s structural heart pipeline prospects based on specific one-year clinical outcome rates.

03

What to watch

Investors may focus on trial design limitations, bleeding/other adverse events not listed here, and whether these results translate into label expansion or reimbursement traction.

Relevance 7/10Novelty 6/10Timing: today, alongside the stock’s reported +2.22% move

Background

VERITAS evaluates the Amulet 360 left atrial appendage occluder in atrial fibrillation patients, targeting stroke prevention while monitoring safety outcomes.

Company-level read

Ticker impact

$ABTBullishMedium confidence
Context

Abbott reports one-year VERITAS results for its Amulet 360 left atrial appendage occluder, with 98%+ stroke-free and >99% pericardial effusion-free rates.

Expected impact

Likely upward bias as the market prices improved probability of continued development and potential regulatory/market adoption.

Evidence & confidence

The article provides specific one-year outcome rates from a named study, which is decision-relevant for pipeline valuation, though it does not mention regulatory approval or a new filing date.

Market effects

Sector

Strength in left atrial appendage occlusion efficacy and safety may be read across to the structural heart device competitive set.

Regional

No clear regional macro linkage beyond US-listed sentiment.

Global

Clinical trial outcomes can influence global expectations for structural heart adoption, but the article provides no geography-specific commercialization details.

Counterpoint

What could challenge this read

Without mention of regulatory submissions, endpoints adjudication details, comparator arms, or durability beyond one year, the market may already be discounting much of the benefit.

Key entities

  • company
    Abbott Laboratories

    US-listed medical device and diagnostics company reporting one-year VERITAS outcomes for Amulet 360.

  • product
    Amulet 360 Left Atrial Appendage Occluder

    Investigational structural heart device evaluated in the VERITAS study.

  • clinical_trial
    VERITAS study

    Clinical study assessing safety and effectiveness of Amulet 360 in atrial fibrillation patients.

Read at source← All news

StoryAbbott reports favorable one-year results for investigational Amulet 360 device

Also covered by

2 outlets

Related articles

NOV 2
$ABTMedAI 9/10

Abbott Touts Favorable Outcomes In Cardiovascular Device Trials

Abbott Laboratories (ABT) presented positive clinical trial results for two cardiovascular devices at a conference. The Amulet 360 LAA Occluder showed 96.3% complete closure in patients, with low complication rates. The SonicForce System achieved 97% procedural success in treating calcified coronary arteries. ABT shares rose 2.55% to $108.91.

finance.yahoo.com2 min
NOV 2
$ABTMedAI 8/10

More than 98% of study patients had no stroke of the most common kind or blood-clot complication for a year.

Abbott (NYSE: ABT) presented one-year results from the VERITAS study of its Amulet 360 LAA Occluder, showing 98% of patients had no stroke or blood-clot complications. The device aims to reduce stroke risk in atrial fibrillation patients. Over 99% of patients had no pericardial effusion requiring intervention, and 98% had no cardiovascular-related mortality. The Amulet 360 features enhanced design for better LAA closure.

stocktitan.net2 min
NOV 2
$ABTMed

Late-breaking one-year data show Abbott's next-generation Amulet 360™ device continues to demonstrate high rates of left atrial appendage closure and low incidence of stroke

Abbott (NYSE: ABT) presented one-year data from the VERITAS study on its Amulet 360 LAA Occluder, showing 96.3% closure rates and low stroke incidence in atrial fibrillation patients. The device is designed to reduce stroke risk and is approved for investigational use in the U.S. and CE Mark in Europe.

prnewswire.com2 min
NOV 1
$ABTMedAI 8/10

Scans found heart-artery calcium fractures after an investigational sound-wave treatment

Abbott's investigational SonicForce Coronary IVL System showed positive results in the TECTONIC study, meeting safety and effectiveness endpoints. The study enrolled 335 patients with severe coronary calcification, reporting a 0.3% 30-day target lesion failure rate and 97% procedural success. The system uses acoustic pressure waves to crack calcium buildup in coronary arteries, potentially expanding Abbott's cardiovascular portfolio.

stocktitan.net2 min
NOV 1
$ABTMedAI 9/10

Abbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce™ Coronary Intravascular Lithotripsy System

Abbott (NYSE: ABT) reported positive 30-day results from its TECTONIC study of the investigational SonicForce Coronary IVL System, which met safety and effectiveness endpoints. The study showed a 0.3% target lesion failure rate and 97% procedural success in treating severe coronary calcification. The system uses acoustic pressure waves to crack calcium buildup in arteries, potentially expanding Abbott's portfolio of cardiovascular devices.

prnewswire.com2 min
OCT 31
$AVGOMed

Notable analyst calls this week: Broadcom, Moderna and Abbott among top picks

Analysts made notable calls this week. D.A. Davidson upgraded Broadcom (AVGO) to Buy with a $400 price target, citing AI-related growth prospects. William Blair downgraded Moderna (MRNA) to Market Perform due to valuation concerns. Argus downgraded Abbott (ABT) to Hold after its reduced growth outlook. Jefferies upgraded Rivian (RIVN) to Buy, citing progress in margins and execution. GF Securities raised AMD's (AMD) price target to $720, expecting strong data center growth.

tradingview.com2 min